Browsing: Updated

Patients and treatmentFrom 16 November 2023 to 29 October 2024, data from 1,038 patients with cutaneous (including acral), clinically detected,…

Bladder cancer treatment has shifted substantially with the incorporation of circulating tumor DNA (ctDNA) status into clinical decision-making, alongside the…

BackgroundOncogenic PIK3CA mutations constitutively activate PI3Kα and drive approximately 40% of hormone receptor–positive (HR+)/HER2-negative (HER2–) breast cancer; however, the toxicity…

BackgroundThe PAM pathway drives breast cancer growth and mediates resistance to endocrine therapy (ET) and CDK4/6 inhibitors (CDK4/6i). Combining PAM…

BackgroundPI3Kα inhibitors (PI3Kαi) demonstrated clinical benefit in approximately 40% of patients with hormone receptor–positive/HER2-negative (HR+/HER2–) advanced breast cancer with PIK3CA…

The FDA has approved the new Guardant360 Liquid CDx, an updated blood-based cancer test designed to support treatment selection in…

BackgroundAt the primary progression-free survival (PFS) analysis, the phase 3 EMBER-3 trial in patients with estrogen receptor–positive/HER2-negative (ER+/HER2–) advanced breast…

BackgroundAt SERENA-6 interim analysis, switching to camizestrant, with continued CDK4/6 inhibitor (CDK4/6 i), at ESR1 mutationemergence during first-line aromatase inhibitor…

The American Society of Clinical Oncology (ASCO) has released new evidence-based recommendations for therapy among patients with stage IV non–small…